{"componentChunkName":"component---common-build-tags-template-js","path":"/tag/gwpharma/","result":{"data":{"allArticle":{"edges":[{"node":{"id":"Article_2765-markdown","title":"FDA Approves Epidiolex, First CBD-Based Drug for Epilepsy","slug":"fda-approves-epidiolex-first-cbd-based-drug-for-epilepsy","content":"Medical marijuana users take note: [The FDA has just approved a new drug containing cannabidiol (CBD)](https://www.cbsnews.com/news/fda-approves-epidiolex-first-marijuana-based-drug-for-seizures/). Its aim is to treat two rare, severe forms of childhood epilepsy.\n\nCreated by U.K. giant GW Pharmaceuticals, Epidiolex is a CBD-based syrup to treat seizures associated with [Lennox-Gastaut syndrome](https://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome) and [Dravet syndrome](https://www.dravetfoundation.org/what-is-dravet-syndrome/) in patients as young as two years old.\n\nResearchers studied Epidiolex’s effectiveness in three randomized, double-blind, placebo-controlled clinical trials involving 516 patients with either syndrome. Epidiolex, taken with other medications, was effective in reducing the frequency of subjects’ seizures.\n\nFOLLOW US ON [FACEBOOK](https://www.facebook.com/pg/hellomdcompany/posts/) & [INSTAGRAM](https://www.instagram.com/hellomd_com/?hl=en)\n\nThis is the first time that the U.S. government has given the green light to a drug derived from CBD. Though CBD is a cannabis compound, it’s non-psychoactive, unlike the other famous cannabinoid, tetrahydrocannabinol (THC).  \n\n“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development,” [says FDA Commissioner Scott Gottlieb in a news release](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm).\n\nThe announcement has led to speculation among experts that a new wave of approved cannabis-based medications may be coming. \n\n“This is a very good development, and it basically underscores that there are medicinal properties to some of the cannabinoids,” [says Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego](https://www.nytimes.com/2018/04/19/health/epidiolex-fda-cannabis-marajuana.html), in a _New York Times_ interview about Epidiolex.\n\n### Epidiolex Pushes CBD Legalization\n\nEpidiolex may become available this fall, but it still has hurdles to clear. One potential roadblock is an investigation into its potential side effects. Also, despite the FDA approval, CBD remains federally illegal. The DEA classifies it as a Schedule 1 drug, defined as “drugs with no currently accepted medical use and a high potential for abuse.” \n\nRELATED: [MARIJUANA LEGALIZATON IS GOING GLOBAL](https://www.hellomd.com/health-wellness/588f897cd5e9e1000c153b31/marijuana-legalization-is-going-global)\n\nBut with Epidiolex’s FDA approval, the DEA may reclassify CBD over the next three months. This will make it possible for patients to purchase the drug with a doctor’s prescription. Already, some drugstore chains such as Rite Aid say they’ll carry it.\n\n### But Does This Mean Cannabis Could Become Legal?\n\nIf CBD gets DEA approval and is put under a new schedule, that doesn’t mean cannabis as a whole will get the green light any time soon. Federal authorities seem to be sticking to a policy of marijuana prohibition, even though a majority of Americans are in favor of legalizing the plant.\n\nThe government only seems to be considering and testing individual cannabis compounds one at a time. Marijuana has so many different compounds and strains that with the government’s current stance, it’s hard to imagine whole cannabis receiving a general stamp of approval.\n\nCBD got FDA approval because it’s an isolated extract that’s been thoroughly studied and tested. It underwent even more testing during the development of Epidiolex, and the drug will meet strict manufacturing standards. \n\nIn fact, Gottlieb warns against other cannabis-based medications making similar claims without this kind of disciplined development: “We’ll continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and work with product developers who are interested in bringing patients safe and effective, high-quality products. But, at the same time, we are prepared to take action when we see the illegal marketing of CBD-containing products with serious, unproven medical claims.”\n\nIt’s worth noting that once given the final go-ahead, Epidiolex will be treated like a traditional pharmaceutical. It will be available through licensed pharmacies, but not at dispensaries where many people currently get their medical marijuana. \n\n### Exploring New Medical Applications of Cannabis \n\nCaution aside, researchers are keen to explore the medical uses of CBD, as well as the potential of tetrahydrocannabinol (THC) and the other 400 or so compounds found in cannabis. There’s already a growing library of research that shows CBD’s potential in treating:\n\n* [Pain](https://www.hellomd.com/health-wellness/5ae222cb049b4f000a64e8eb/how-cbd-can-help-relieve-endometriosis-pain) \n* [Parkinson’s disease](https://www.hellomd.com/health-wellness/5a1c9b13eea891000897e271/marijuanas-role-in-helping-parkinsons-disease-patients)\n* [Multiple sclerosis](https://www.hellomd.com/health-wellness/5936cf68a81c05002adae2f7/new-studies-indicate-cannabis-helps-with-multiple-sclerosis)\n* [Tourette’s syndrome](https://www.hellomd.com/health-wellness/59e53141d652260aa3917b7d/studies-show-cannabis-may-help-with-tourette-syndrome)\n* [Glaucoma](https://www.hellomd.com/health-wellness/5acd032ff24d1300077ccbc8/how-does-cannabis-affect-your-eyes)\n* [Schizophrenia](https://www.hellomd.com/health-wellness/596d4c6768ca41512d3fe146/cbd-helps-alleviate-symptoms-of-schizophrenia)\n* [Inflammation](https://www.hellomd.com/health-wellness/5abeac04f24d1300077ccbae/how-cannabis-can-help-ease-arthritis-pain-and-inflammation)\n* [Anxiety]( https://www.hellomd.com/health-wellness/5a99f400f24d1300077ccb72/finding-success-with-cannabis-to-reduce-anxiety) \n\nThe list of potential applications for diseases and conditions is nearly endless.\n\nFor its part, GW Pharmaceuticals has also [developed a new CBD-based nasal spray, Sativex, that relieves pain and has been approved by the British government](http://www.businessinsider.com/what-is-cbd-in-marijuana-2018-2).\n\n“Advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” says Gottlieb.\n\n### Not All CBD Medications Are Created Equal\n\n“Sound development” is the key here. Gottlieb and other medical experts warn that not all CBD-based medications are created equal. \n\nIn states where cannabis is legal, or in ones that have laws legalizing CBD only, CBD-infused oils and salves are sold through dispensaries. A 2017 study published in the _Journal of the American Medical Association_ found that [the levels of CBD contained in products from 31 different sellers were often different than the amounts shown on labels](https://jamanetwork.com/journals/jama/article-abstract/2661569). And in some cases THC was present, even though it wasn’t listed.\n\nThat said, you can’t put the genie back in the bottle. The testimony of people who have successfully used non-prescription CBD to treat childhood epilepsy and other conditions is hard to ignore. And given the choice between paying to go see a doctor for an expensive prescription or getting CBD from their usual supplier, people will often go with what they know and trust. Hopefully, Epidiolex is just the beginning of regulated, effective CBD medicine that will be made available to those who need it. \n\nPhoto credit: [Annie Spratt](https://unsplash.com/@anniespratt)\n\nIf you’re new to cannabis and want to learn more, take a look at our [Cannabis 101](https://www.hellomd.com/health-wellness/56201c206430320006bb0000/cannabis-101-your-quick-guide-to-medical-marijuana) post. [HelloMD](https://www.hellomd.com/) can help you get your medical marijuana recommendation; it's easy, private and 100% online.  \n","image":{"childImageSharp":{"fluid":{"base64":"data:image/jpeg;base64,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","aspectRatio":1.3793103448275863,"src":"/static/c41316ddb83ad71f6afa997fe85218ea/14b42/7a2086394acad1ffab0c9a3bbb00cdd8.jpg","srcSet":"/static/c41316ddb83ad71f6afa997fe85218ea/f836f/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 200w,\n/static/c41316ddb83ad71f6afa997fe85218ea/2244e/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 400w,\n/static/c41316ddb83ad71f6afa997fe85218ea/14b42/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 800w,\n/static/c41316ddb83ad71f6afa997fe85218ea/47498/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 1200w,\n/static/c41316ddb83ad71f6afa997fe85218ea/0e329/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 1600w,\n/static/c41316ddb83ad71f6afa997fe85218ea/e0e30/7a2086394acad1ffab0c9a3bbb00cdd8.jpg 3660w","srcWebp":"/static/c41316ddb83ad71f6afa997fe85218ea/58556/7a2086394acad1ffab0c9a3bbb00cdd8.webp","srcSetWebp":"/static/c41316ddb83ad71f6afa997fe85218ea/61e93/7a2086394acad1ffab0c9a3bbb00cdd8.webp 200w,\n/static/c41316ddb83ad71f6afa997fe85218ea/1f5c5/7a2086394acad1ffab0c9a3bbb00cdd8.webp 400w,\n/static/c41316ddb83ad71f6afa997fe85218ea/58556/7a2086394acad1ffab0c9a3bbb00cdd8.webp 800w,\n/static/c41316ddb83ad71f6afa997fe85218ea/99238/7a2086394acad1ffab0c9a3bbb00cdd8.webp 1200w,\n/static/c41316ddb83ad71f6afa997fe85218ea/7c22d/7a2086394acad1ffab0c9a3bbb00cdd8.webp 1600w,\n/static/c41316ddb83ad71f6afa997fe85218ea/46196/7a2086394acad1ffab0c9a3bbb00cdd8.webp 3660w","sizes":"(max-width: 800px) 100vw, 800px"}}}}},{"node":{"id":"Article_2702-markdown","title":"Big Pharma & Cannabis: 5 Trends to Watch ","slug":"big-pharma-and-cannabis-5-trends-to-watch","content":"The pharmaceutical industry has long been an opponent of cannabis legalization. It’s no surprise, because when people turn to marijuana for medical purposes, they often turn away from pharmaceuticals. But now, as more states remove hurdles for recreational marijuana use, the trend is shifting—with Big Pharma starting to make forays into the cannabis industry. \n\nThere are a lot of questions about the drug industry’s apparent about-face regarding cannabis. How is Big Pharma changing its strategies to mainstream manufactured cannabis products? How are synthetic cannabis pharmaceuticals legally hitting the market when marijuana is still illegal federally? How will Big Pharma’s pursuits likely impact local marijuana growers and small cannabis businesses? \n\nYou’ll find the answers to these and other questions in the following five trends we see with Big Pharma getting in on the green rush. \n\nFOLLOW US ON [FACEBOOK](https://www.facebook.com/pg/hellomdcompany/posts/) & [INSTAGRAM](https://www.instagram.com/hellomd_com/?hl=en)\n\n### 1. Big Pharma Taps the Global Cannabis Market\n\nStrategic partnerships between cannabis producers and Big Pharma have the potential to expand global access to cannabis. The Canadian cannabis market offers an interesting case study to explore the benefits of collaboration with unlikely allies. \n\nIn the first formal agreement of its kind, [cannabis licensed producer (LP) Tilray and pharmaceutical giant Canada Sandoz are working together to develop new non-combustible cannabis products](http://business.financialpost.com/cannabis/big-pharmas-first-foray-into-cannabis-arrives-with-sandoz-tilray-deal). These include gel caps, edibles and sprays—even though they’re not yet legal in Canada. Along with new products, Tilray and other LPs are looking to pharmacies to officially distribute their new cannabis products. \n\nWhat does all this mean for consumers? It means that cannabis will probably be exported and distributed in more global markets—as a biotech product. In addition, Big Pharma is entering the ring as an industry player, rather than as an opponent—meaning, they’re looking to expand access to cannabis, not thwart it. \n\nTilray’s Chief Executive Officer Brendan Kennedy thinks this is a good thing. In a recent interview with _VICE News_, Brendan comments that as Canada builds its reputation as a “safe and reliable source of medical cannabis,” [it can use the considerable resources of a global pharmaceutical company to educate medical providers about marijuana](https://news.vice.com/en_ca/article/ywxzdw/big-pharma-has-officially-entered-the-canadian-cannabis-industry). This will in turn make cannabis more accessible to patients around the world.  \n\nOr so the thinking goes.  \n\nTime will tell if these types of partnerships bring about more education and access, or if they’ll simply lead to more outrageous profits for Big Pharma at the expense of smaller cannabis producers and patients alike. \n\n### 2. Synthetic Marijuana Qualifies for Schedule 2 & 3 Classifications \n\nBig Pharma’s two-pronged approach to entering the mainstream cannabis market relies on industry partnerships and producing its own cannabis products. This is interesting given Big Pharma’s history in blocking marijuana legalization on the state level.\n\nLet’s not forget what happened in Arizona, when a pharmaceutical company called Insys paid $500,000 to [halt a measure that would have legalized recreational marijuana](https://hightimes.com/news/shady-pharma-company-sabotages-legal-weed-and-gets-dea-approval-for-synthetic-thc/). This happened just as Insys prepared to launch its own drug made with synthetic tetrahydrocannabinol (THC). \n\nSo far, the FDA has approved three lab-made, THC-based drugs: Marinol, Syndros and Cesamet, all to help reduce nausea, vomiting and weight loss associated with cancer and HIV/AIDS. These pharmaceutical companies’ products are receiving a Schedule 2 or 3 rating by the U.S. Drug Enforcement Administration (DEA).\n\nThis in turn makes it easy for Big Pharma to enter the mainstream drug market with laboratory-produced cannabis—much easier than marijuana producers growing botanical cannabis, which is still classified as a [Schedule 1 substance](https://www.dea.gov/druginfo/ds.shtml).  \n\n### 3. Marijuana Research & Clinical Trials Take Place Overseas \n\nSo, we know that Big Pharma is actively producing synthetic cannabis, and companies are investing millions of dollars in research and development (R&D) to create cannabis-based medicine. According to U.S. Food and Drug Administration (FDA) guidelines, \"Study of marijuana in clinical trial settings is needed to assess the safety and effectiveness of marijuana for medical use.\" \n\nBut how is this happening when cannabis is still a Schedule 1 substance? It turns out the clinical trials for these synthetic marijuana drugs aren’t carried out on American soil where federal cannabis prohibition remains firm. Instead, many drug companies are [running the first two phases of their cannabis clinical trials in places like Israel](https://www.rollingstone.com/culture/features/how-booming-israeli-weed-industry-is-changing-american-pot-w499117).\n\nIsrael has policies to support researchers in investigating many aspects of the cannabis plant and its effects on the body. So, some American pharmaceutical companies are starting their R&D process in Israel, then completing phase 3 of their trials in the U.S. for quicker FDA approval. \n\nAn early adopter of this trend is GW Pharmaceuticals. This U.K.-U.S. company just received a [green light from the FDA for its new epilepsy drug, Epidiolex](http://www.businessinsider.com/marijuana-epilepsy-drug-approval-2018-4). If approved by vote in June, it will be the first cannabidiol (CBD)-based pharmaceutical on the market. \n\n### 4. Big Pharma’s Profits Will Decrease Slightly as Legalized Cannabis Sales Go Up \n\nOnce the federal government finally allows medical marijuana to become a legitimate part of the health-care industry, those pharmaceutical companies not invested in cannabis could suffer financial losses. According to a 2016 report using data from the University of Georgia, [Medicare prescriptions decreased significantly in states where medical marijuana is legal](https://www.salon.com/2017/05/27/medical-marijuana-could-cost-big-pharma-4-billion-a-year_partner/).\n\nAnalysts predict that legal marijuana use for ailments from chronic pain to epileptic seizures to glaucoma may cost Big Pharma about $5 million dollars. However, seeing as the drug industry makes about $425 billion per year, this isn’t going to affect Big Pharma’s bottom line that much. \n\n### 5. Politicians Recognize Marijuana as Part Solution to the Opioid Crisis\n\nMarijuana is often stigmatized as a “gateway drug” for other more addictive and harmful substances. Yet [two-thirds of drug deaths in 2017 were caused by opioids](https://www.cbsnews.com/news/opioid-fentanyl-overdose-deaths-us-life-expectancy-drops-for-second-year/). According to a 2018 Centers for Disease Control & Prevention report, opioid abuse is on the rise in nearly every segment of American society, claiming 115 lives every day.\n\nRELATED: [MARIJUANA TAKES ON BIG PHARMA ON THE OPIOID FRONT](https://www.hellomd.com/health-wellness/578e5cb0687e76000700000c/marijuana-takes-on-big-pharma-on-the-opioid-front)\n\nEvidence-based research shows that marijuana consumption can help decrease prescription drug use. Cannabis’s healing properties make it a viable alternative to anti-anxiety and antidepressant medication, anti-seizure medication, painkillers and sleeping pills. According to a recent _Journal of Health Economics_ study, “marijuana is a far less addictive substance than opioids and the potential for overdosing is nearly zero.” \n\nLegislators are using federally funded research to take a stand against anti-legalization lobbying groups, including Big Pharma. In response to a [question posed to her on “Good Day New York” about marijuana being a gateway drug, Sen. Kirsten Gillibrand (D-NY) said](https://www.forbes.com/sites/tomangell/2018/02/23/senator-calls-out-big-pharma-for-opposing-legal-marijuana/#50f2385a1bac), \"I don't see it as a gateway to opioids. What I see is the opioid industry and the drug companies that manufacture it, some of them in particular, are just trying to sell more drugs that addict patients and addict people across this country.” \n\nIt’s time for marijuana’s efficacy as an alternative treatment to further come into the light through federally funded, peer-reviewed research. In order to disrupt the grip of Big Pharma and ultimately decrease opioid addiction, more supportive data and collaboration among physicians, lawmakers and influential players within the cannabis industry are sorely needed. Ironically, it’s the R&D investment and start-up capital from Big Pharma that could help push the ball forward on necessary research. \n\n### Will Big Pharma’s Entry Into Cannabis Help or Harm the Industry?\n\nBig Pharma’s presence in cannabis is inevitable (despite its best early attempts to sabotage marijuana businesses to protect their own interests). On the up side, strategic partnerships between cannabis producers and pharmaceutical companies will likely expand access to marijuana-based healing. And while this may produce a marketplace that’s more limited than that of a completely legal whole-plant cannabis market, having these partnerships will also drive innovative research that will hopefully further spur the FDA and DEA to re-evaluate federal laws around cannabis regulation. \n\nAs always, there can be major cons when big businesses co-opt production and distribution. One concern is over the quality of synthetic cannabis therapies. Many assert that synthetics aren’t as effective as whole-plant marijuana is. That said, these pharmaceuticals do provide relief for many, especially children suffering from epilepsy and other health conditions.\n\nAnother worry is that drug companies will come in and capture the lion’s share of the profits—after all, they have their shareholders’ best interests in mind. This profit motive will put the squeeze on small, local growers who lack the resources that Big Pharma has. \n\nBig Pharma’s involvement in cannabis will be both good and bad for those of us who’ve come to rely on the plant’s many medicinal benefits. Whether the bad will outweigh the good, or vice versa, has yet to be seen.\n\nPhoto credit: [Chris Potter](https://www.flickr.com/photos/86530412@N02/)\n\nIf you’re new to cannabis and want to learn more, take a look at our [Cannabis 101]( https://www.hellomd.com/health-wellness/56201c206430320006bb0000/cannabis-101-your-quick-guide-to-medical-marijuana) post. [HelloMD](https://www.hellomd.com/) can help you get your medical marijuana recommendation; it's easy, private and 100% online.  \n","image":{"childImageSharp":{"fluid":{"base64":"data:image/jpeg;base64,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","aspectRatio":1.3605442176870748,"src":"/static/278143fd32a8e6e75c26ae6857535257/f28e0/bdd751495325517767373e1cc8449150.jpg","srcSet":"/static/278143fd32a8e6e75c26ae6857535257/f836f/bdd751495325517767373e1cc8449150.jpg 200w,\n/static/278143fd32a8e6e75c26ae6857535257/2244e/bdd751495325517767373e1cc8449150.jpg 400w,\n/static/278143fd32a8e6e75c26ae6857535257/f28e0/bdd751495325517767373e1cc8449150.jpg 468w","srcWebp":"/static/278143fd32a8e6e75c26ae6857535257/be191/bdd751495325517767373e1cc8449150.webp","srcSetWebp":"/static/278143fd32a8e6e75c26ae6857535257/61e93/bdd751495325517767373e1cc8449150.webp 200w,\n/static/278143fd32a8e6e75c26ae6857535257/1f5c5/bdd751495325517767373e1cc8449150.webp 400w,\n/static/278143fd32a8e6e75c26ae6857535257/be191/bdd751495325517767373e1cc8449150.webp 468w","sizes":"(max-width: 468px) 100vw, 468px"}}}}}]}},"pageContext":{"limit":12,"skip":0,"numPages":1,"currentPage":1,"id":5303,"name":"Gwpharma","slug":"gwpharma","country":"US"}},"staticQueryHashes":["3949754563","4179947113","4202924991"]}